FY2025 EPS Estimates for Surmodics Increased by Analyst

Surmodics, Inc. (NASDAQ:SRDX) – Analysts at Zacks Research increased their FY2025 earnings per share estimates for Surmodics in a research note issued on Tuesday, January 28th. Zacks Research analyst D. Dey now forecasts that the company will post earnings of $0.17 per share for the year, up from their prior estimate of $0.16. The consensus estimate for Surmodics’ current full-year earnings is $0.19 per share. Zacks Research also issued estimates for Surmodics’ Q4 2026 earnings at $0.27 EPS, FY2026 earnings at $0.83 EPS and FY2027 earnings at $0.88 EPS.

Surmodics (NASDAQ:SRDX) last announced its quarterly earnings results on Thursday, January 30th. The company reported ($0.04) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.04. Surmodics had a negative net margin of 9.15% and a negative return on equity of 3.79%.

SRDX has been the topic of several other reports. Needham & Company LLC reissued a “hold” rating on shares of Surmodics in a research report on Thursday, November 7th. StockNews.com began coverage on shares of Surmodics in a research note on Sunday. They set a “hold” rating on the stock. Five investment analysts have rated the stock with a hold rating, Based on data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $50.00.

Surmodics Price Performance

NASDAQ:SRDX opened at $35.78 on Thursday. The business’s 50-day moving average is $38.88 and its two-hundred day moving average is $39.23. Surmodics has a 12 month low of $25.17 and a 12 month high of $42.44. The company has a debt-to-equity ratio of 0.25, a current ratio of 3.96 and a quick ratio of 3.22.

Insider Buying and Selling at Surmodics

In other news, CFO Timothy J. Arens sold 7,009 shares of the firm’s stock in a transaction dated Tuesday, November 26th. The shares were sold at an average price of $39.44, for a total transaction of $276,434.96. Following the completion of the transaction, the chief financial officer now owns 70,350 shares in the company, valued at approximately $2,774,604. This trade represents a 9.06 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. 8.90% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Surmodics

Hedge funds and other institutional investors have recently modified their holdings of the stock. Modus Advisors LLC purchased a new position in shares of Surmodics in the fourth quarter worth approximately $40,000. Quest Partners LLC grew its position in Surmodics by 107,100.0% during the third quarter. Quest Partners LLC now owns 1,072 shares of the company’s stock valued at $42,000 after purchasing an additional 1,071 shares in the last quarter. SG Americas Securities LLC increased its stake in Surmodics by 22.1% in the 4th quarter. SG Americas Securities LLC now owns 6,940 shares of the company’s stock valued at $275,000 after buying an additional 1,255 shares during the period. R Squared Ltd purchased a new stake in Surmodics in the 4th quarter worth approximately $55,000. Finally, Charles Schwab Investment Management Inc. boosted its stake in shares of Surmodics by 1.3% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 116,311 shares of the company’s stock valued at $4,511,000 after buying an additional 1,491 shares during the period. Institutional investors and hedge funds own 96.63% of the company’s stock.

Surmodics Company Profile

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).